ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
An analog of polyethylene glycol (PEG) causes fewer immune reactions than PEG. PEG conjugation has been widely used to increase the longevity of drug action and protect drug molecules from being attacked by the immune system. However, prior exposure to PEG from its widespread use in consumer products, foods, and drugs has caused many people to develop immune reactions to the polymer itself, potentially reducing the efficacy of PEGylated drugs and causing unwanted side effects. To address this problem, Ashutosh Chilkoti of Duke University and coworkers developed a brush polymer called POEGMA, poly[oligo(ethylene glycol) methyl ether methacrylate], as a PEG substitute (Nat. Biomed. Eng. 2016, DOI: 10.1038/s41551-016-0002). They used a technique called in situ atom transfer radical polymerization to conjugate POEGMAs having different numbers of ethylene glycol side chains to exendin-4, a therapeutic peptide used clinically to treat type 2 diabetes. The conjugates reduced or eliminated immune interactions with preexisting PEG antibodies in patient plasma samples compared with those of two FDA-approved PEGylated protein drugs. And the conjugates didn’t reduce drug efficacy, as tested in mice. The findings suggest that POEGMA may be an attractive next-generation replacement for PEGylation of peptide and protein drugs.
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on X